Janssen CAR-T is Priority Medicine in EU, and moreEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XJanssen CAR-T is Priority Medicine in EU, and morehttps://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/
Oncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerWill it happen or not? There are doubts about whether the proposed $74 billion merger of cancer drug Share XOncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerhttps://pharmaphorum.com/views-analysis-oncology/oncology-round-up-shareholders-question-bms-celgene-merger-while-merck-cos-keytruda-keeps-getting-stronger/
Oncology round-up: CAR-T conference raises hopes for solid tumour therapyKisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it Share XOncology round-up: CAR-T conference raises hopes for solid tumour therapyhttps://pharmaphorum.com/views-and-analysis/oncology-round-up-car-t-conference-raises-hopes-for-solid-tumour-therapy/
2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU marketOncology drugs are developing at a fast pace, but 2018 was the year when immune-oncology set new standards Share X2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU markethttps://pharmaphorum.com/views-analysis-oncology/2018-in-review-merck-co-sets-new-standards-in-oncology-car-ts-hit-eu-market/
AstraZeneca looks to CRISPR to boost success ratesBetween 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below Share XAstraZeneca looks to CRISPR to boost success rateshttps://pharmaphorum.com/views-and-analysis/astrazeneca-crispr-boost-success-rates/
Merck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKMerck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in Share XMerck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/merck-cancer-blockbuster-keytruda-funds-rare-disease/
Dreaming big with small moleculesClovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved Share XDreaming big with small moleculeshttps://pharmaphorum.com/views-analysis-oncology/dreaming-big-small-molecules/
Has the NHS joined the biosimilars revolution?Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Share XHas the NHS joined the biosimilars revolution?https://pharmaphorum.com/oncology/nhs-joined-biosimilar-revolution/
How the NHS got ahead of the curve with CAR-TThe UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies. Richard Staines Share XHow the NHS got ahead of the curve with CAR-Thttps://pharmaphorum.com/views-analysis-oncology/nhs-got-ahead-curve-car-t/
